BCM
ADAP

Bayesian Capital Management’s Adaptimmune Therapeutics ADAP Stock Holding History

Bayesian Capital Management’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-10,486
Closed -$8.18K – 711
2023
Q3 		$8.18K Sell
10,486
-1,100
-9% -$923 ﹤0.01% 660
2023
Q2 		$10.7K Sell
11,586
-3,200
-22% -$3.81K ﹤0.01% 748
2023
Q1 		$16.1K Buy
+14,786
New +$22.9K ﹤0.01% 736

Other funds holding ADAP

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Bayesian Capital Management's ADAP Position: Q4 2023 in Review

Bayesian Capital Management sold out of Adaptimmune Therapeutics (ADAP) in Q4 2023, closing a stake of 10,486 shares — an estimated $8.18K sold.

Bayesian Capital Management first reported a position in ADAP in Q1 2023 and held it in 3 quarters. The position peaked at $16.1K in Q1 2023. 79 funds tracked by Wall St. Rank hold ADAP as of Q4 2023.

  • Bayesian Capital Management reported no remaining Adaptimmune Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Bayesian Capital Management sold 10,486 Adaptimmune Therapeutics shares in Q4 2023, an estimated $8.18K.
  • Bayesian Capital Management first reported a position in Adaptimmune Therapeutics in Q1 2023 and held it in 3 quarters.
  • Bayesian Capital Management's Adaptimmune Therapeutics position peaked at $16.1K in Q1 2023.
  • 79 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q4 2023.

Based on Bayesian Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.